Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia
Authors:
- 26 July 2007
- journal article
- Published by Springer Nature in Leukemia
- Vol. 21 (11) , 2240-2245
Abstract
CMC-544 (inotuzumab ozogamicin) is a CD22-specific cytotoxic immunoconjugate of calicheamicin intended for the treatment of B-lymphoid malignancies. This preclinical study investigated antitumor activity of CMC-544 against CD22+ acute lymphoblastic leukemia (ALL). CMC-544 inhibited in vitro growth of ALL cell lines more potently than that of Ramos B-lymphoma cells. When administered to nude mice with established sc xenografts of REH ALL, CMC-544 caused dose-dependent inhibition of xenograft growth producing complete tumor regression and cures in tumor-bearing mice at the highest dose of 160 g/kg of conjugated calicheamicin. In contrast, a nonbinding control conjugate was 16-fold less effective than CMC-544 in inhibiting growth of REH ALL xenografts. When REH cells were injected intravenously in scid mice and allowed to disseminate systemically, mice developed hind-limb paralysis that was effectively prevented by treatment with CMC-544. Flow cytometric analysis of cells recovered from the bone marrow from mice with disseminated disease verified the presence of engrafted ALL cells. Significantly reduced numbers of ALL cells were recovered from the bone marrow of CMC-544-treated mice than from vehicle-treated mice with disseminated disease. The anti-leukemia activity of CMC-544 demonstrated here further supports clinical evaluation of CMC-544 for the treatment of CD22+ leukemia.Keywords
This publication has 24 references indexed in Scilit:
- Identification of Candidate Target Antigens for Antibody-Based Immunotherapy in Childhood B-Cell Precursor ALLKlinische Padiatrie, 2006
- Cancer Incidence and Incidence Rates in Japan in 2000: Estimates Based on Data from 11 Population-Based Cancer RegistriesJapanese Journal of Clinical Oncology, 2006
- Treatment of Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2006
- Immunophenotyping of acute leukaemiasImmunology Letters, 2005
- Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell LymphomaClinical Cancer Research, 2004
- Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignanciesBlood, 2004
- Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicinLeukemia, 2003
- CD22, A B LYMPHOCYTE–SPECIFIC ADHESION MOLECULE THAT REGULATES ANTIGEN RECEPTOR SIGNALING*Annual Review of Immunology, 1997
- Calicheamicin γ 1 I : an Antitumor Antibiotic That Cleaves Double-Stranded DNA Site SpecificallyScience, 1988
- Heterogeneity of genomic fusion of BCR and ABL in Philadelphia chromosome-positive acute lymphoblastic leukemia.Proceedings of the National Academy of Sciences, 1988